Anders Hallberg Selected Research

compound 21

11/2021	Seven days treatment with the angiotensin II type 2 receptor agonist C21 in hospitalized COVID-19 patients; a placebo-controlled randomised multi-centre double-blind phase 2 trial.
1/2020	Evolution of Angiotensin Peptides and Peptidomimetics as Angiotensin II Receptor Type 2 (AT2) Receptor Agonists.
1/2016	Angiotensin AT2-receptor stimulation improves survival and neurological outcome after experimental stroke in mice.
1/2015	Direct angiotensin type 2 receptor (AT2R) stimulation attenuates T-cell and microglia activation and prevents demyelination in experimental autoimmune encephalomyelitis in mice.
3/2014	Angiotensin type 2 receptor stimulation ameliorates left ventricular fibrosis and dysfunction via regulation of tissue inhibitor of matrix metalloproteinase 1/matrix metalloproteinase 9 axis and transforming growth factor β1 in the rat heart.
1/2014	Direct angiotensin AT2 receptor stimulation using a novel AT2 receptor agonist, compound 21, evokes neuroprotection in conscious hypertensive rats.
3/2013	AT2-receptor stimulation enhances axonal plasticity after spinal cord injury by upregulating BDNF expression.
1/2013	Angiotensin II type 2 receptor promotes adipocyte differentiation and restores adipocyte size in high-fat/high-fructose diet-induced insulin resistance in rats.
4/2011	Non-peptide AT2-receptor agonists.
4/2010	Direct angiotensin II type 2 receptor stimulation acts anti-inflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor kappaB.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Anders Hallberg Research Topics

Disease

7	Malaria 09/2006 - 03/2003
4	Infarction (Infarctions) 01/2016 - 12/2008
3	Inflammation (Inflammations) 01/2011 - 07/2003
2	Stroke (Strokes) 01/2016 - 01/2014
2	Fibrosis (Cirrhosis) 03/2014 - 12/2009
2	Myocardial Infarction 04/2011 - 12/2008
2	Acquired Immunodeficiency Syndrome (AIDS) 11/2004 - 04/2003
1	COVID-19 11/2021
1	Idiopathic Pulmonary Fibrosis 01/2020
1	Neuralgia (Stump Neuralgia) 02/2016
1	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 01/2016
1	HIV Infections (HIV Infection) 01/2015
1	Demyelinating Diseases (Demyelinating Disease) 01/2015
1	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/2015
1	Multiple Sclerosis 01/2015
1	Hyperandrogenism 09/2014
1	Polycystic Ovary Syndrome (Syndrome, Stein-Leventhal) 09/2014
1	Brain Injuries (Brain Injury) 01/2014
1	Ischemia 01/2014
1	Spinal Cord Compression 03/2013
1	Spinal Cord Injuries (Spinal Cord Injury) 03/2013
1	Hyperinsulinism (Hyperinsulinemia) 01/2013
1	Insulin Resistance 01/2013
1	Hypertension (High Blood Pressure) 04/2011
1	Cardiovascular Diseases (Cardiovascular Disease) 04/2011
1	Cognitive Dysfunction 01/2011
1	Alzheimer Disease (Alzheimer's Disease) 01/2011
1	Pneumocystis Pneumonia (Pneumocystis carinii Pneumonia) 05/2004
1	Crohn Disease (Crohn's Disease) 07/2003
1	Colitis 07/2003

Drug/Important Bio-Agent (IBA)

11	compound 21IBA 11/2021 - 12/2008
8	Peptide Hydrolases (Proteases)FDA Link 01/2015 - 03/2003
7	plasmepsin (plasmepsin I)IBA 09/2006 - 03/2003
6	Type 2 Angiotensin ReceptorIBA 11/2021 - 12/2008
5	Peptides (Polypeptides)IBA 01/2020 - 01/2011
4	Pharmaceutical PreparationsIBA 01/2020 - 01/2004
3	statineIBA 06/2005 - 03/2003
2	AngiotensinsIBA 01/2016 - 01/2015
2	Brain-Derived Neurotrophic Factor (BDNF)IBA 01/2016 - 03/2013
2	Hemoglobins (Hemoglobin)IBA 09/2006 - 01/2004
2	Human immunodeficiency virus 1 p16 proteaseIBA 11/2004 - 04/2003
2	Aspartic Acid ProteasesIBA 06/2004 - 08/2003
2	Tetrahydrofolate Dehydrogenase (Dihydrofolate Reductase)IBA 05/2004 - 07/2003
1	VaccinesIBA 11/2021
1	PeptidomimeticsIBA 01/2020
1	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 02/2016
1	Angiotensin Receptors (Angiotensin II Receptor)IBA 02/2016
1	GAP-43 Protein (GAP 43 Protein)IBA 01/2016
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2016
1	trkB ReceptorIBA 01/2016
1	Reverse Transcriptase InhibitorsIBA 01/2015
1	InterferonsIBA 01/2015
1	LipopolysaccharidesIBA 01/2015
1	Nonesterified Fatty Acids (NEFA)IBA 09/2014
1	Fatty Acids (Saturated Fatty Acids)IBA 09/2014
1	CollagenIBA 03/2014
1	Transforming Growth Factors (Transforming Growth Factor)IBA 03/2014
1	Matrix Metalloproteinase 1 (Interstitial Collagenase)IBA 03/2014
1	Matrix Metalloproteinase 9 (Gelatinase B)IBA 03/2014
1	PD 123319IBA 01/2014
1	Endothelin-1 (Endothelin 1)IBA 01/2014
1	Neuroprotective AgentsIBA 01/2014
1	Losartan (Cozaar)FDA LinkGeneric 01/2013
1	FructoseIBA 01/2013
1	NeuropeptidesIBA 01/2011
1	Amyloid (Amyloid Fibrils)IBA 01/2011
1	Angiotensin IIIBA 01/2011
1	indium-bleomycinIBA 04/2010
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 04/2010
1	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 04/2010
1	AldosteroneIBA 12/2009
1	Caspase 3 (Caspase-3)IBA 12/2008
1	Fas Ligand Protein (Fas Ligand)IBA 12/2008
1	EstersIBA 05/2004
1	plasmepsin IIIBA 01/2004
1	Methotrexate (Mexate)FDA LinkGeneric 07/2003
1	Peroxidase (Myeloperoxidase)IBA 07/2003
1	Folic Acid AntagonistsIBA 07/2003
1	SolutionsIBA 03/2003

Therapy/Procedure

1	Aftercare (After-Treatment) 09/2014
1	Ligation 12/2008
1	Catheters 12/2008